Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free SNCA Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Seneca Biopharma (SNCA) Competitors

Seneca Biopharma logo
Compare

SNCA vs. JATT, IZTC, ALVR, ZIVO, and FNCH

Should you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include JATT Acquisition (JATT), Invizyne Technologies (IZTC), AlloVir (ALVR), ZIVO Bioscience (ZIVO), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.

How does Seneca Biopharma compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

JATT Acquisition has higher earnings, but lower revenue than Seneca Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
Seneca Biopharma$10K3,234.35-$8.35MN/AN/A

JATT Acquisition has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. JATT Acquisition's return on equity of -49.58% beat Seneca Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
Seneca Biopharma -230.34%-122.20%-110.61%

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 5.2% of Seneca Biopharma shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 2.1% of Seneca Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Seneca Biopharma'saverage media sentiment score.

Company Overall Sentiment
JATT Acquisition Neutral
Seneca Biopharma Neutral

Summary

JATT Acquisition beats Seneca Biopharma on 6 of the 7 factors compared between the two stocks.

How does Seneca Biopharma compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

5.2% of Seneca Biopharma shares are owned by institutional investors. 2.1% of Seneca Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Invizyne Technologies had 1 more articles in the media than Seneca Biopharma. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Seneca Biopharma. Invizyne Technologies' average media sentiment score of 0.00 equaled Seneca Biopharma'saverage media sentiment score.

Company Overall Sentiment
Invizyne Technologies Neutral
Seneca Biopharma Neutral

Invizyne Technologies has higher earnings, but lower revenue than Seneca Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Seneca Biopharma$10K3,234.35-$8.35MN/AN/A

Invizyne Technologies has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Invizyne Technologies' return on equity of 0.00% beat Seneca Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Seneca Biopharma -230.34%-122.20%-110.61%

Summary

Invizyne Technologies beats Seneca Biopharma on 4 of the 7 factors compared between the two stocks.

How does Seneca Biopharma compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 5.2% of Seneca Biopharma shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 2.1% of Seneca Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AlloVir has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. AlloVir's return on equity of -71.03% beat Seneca Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
AlloVirN/A -71.03% -61.27%
Seneca Biopharma -230.34%-122.20%-110.61%

Seneca Biopharma has higher revenue and earnings than AlloVir.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/A-$190.42M-$20.23N/A
Seneca Biopharma$10K3,234.35-$8.35MN/AN/A

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Seneca Biopharma'saverage media sentiment score.

Company Overall Sentiment
AlloVir Neutral
Seneca Biopharma Neutral

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Seneca Biopharma has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Summary

AlloVir beats Seneca Biopharma on 5 of the 8 factors compared between the two stocks.

How does Seneca Biopharma compare to ZIVO Bioscience?

Seneca Biopharma (NASDAQ:SNCA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

5.2% of Seneca Biopharma shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 2.1% of Seneca Biopharma shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ZIVO Bioscience has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. ZIVO Bioscience's return on equity of 0.00% beat Seneca Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Seneca Biopharma-230.34% -122.20% -110.61%
ZIVO Bioscience N/A N/A -2,240.92%

ZIVO Bioscience has higher revenue and earnings than Seneca Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seneca Biopharma$10K3,234.35-$8.35MN/AN/A
ZIVO Bioscience$15.85K1,073.09-$7.78M-$2.18N/A

In the previous week, Seneca Biopharma's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company Overall Sentiment
Seneca Biopharma Neutral
ZIVO Bioscience Neutral

Seneca Biopharma has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.

Summary

ZIVO Bioscience beats Seneca Biopharma on 6 of the 9 factors compared between the two stocks.

How does Seneca Biopharma compare to Finch Therapeutics Group?

Seneca Biopharma (NASDAQ:SNCA) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

5.2% of Seneca Biopharma shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 2.1% of Seneca Biopharma shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Finch Therapeutics Group has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Finch Therapeutics Group's return on equity of -69.14% beat Seneca Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Seneca Biopharma-230.34% -122.20% -110.61%
Finch Therapeutics Group N/A -69.14%-26.92%

Seneca Biopharma has higher revenue and earnings than Finch Therapeutics Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seneca Biopharma$10K3,234.35-$8.35MN/AN/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

In the previous week, Seneca Biopharma's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company Overall Sentiment
Seneca Biopharma Neutral
Finch Therapeutics Group Neutral

Seneca Biopharma has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Summary

Finch Therapeutics Group beats Seneca Biopharma on 5 of the 8 factors compared between the two stocks.

Get Seneca Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNCA vs. The Competition

Export
MetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$32.34M$329.01M$6.25B$11.77B
Dividend YieldN/AN/A2.74%5.26%
P/E RatioN/AN/A29.2527.07
Price / Sales3,234.35189.48504.6873.43
Price / CashN/A22.4443.3053.90
Price / Book1.414.739.676.69
Net Income-$8.35M-$132.96M$3.55B$332.64M

Seneca Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNCA
Seneca Biopharma
N/A$1.87
-2.1%		N/AN/A$32.34M$10KN/A7
JATT
JATT Acquisition
N/A$10.75
+2.4%		N/AN/A$83.85MN/AN/A3
IZTC
Invizyne Technologies
N/A$9.98
-3.6%		N/AN/A$62.40MN/AN/A29
ALVR
AlloVir
N/A$5.46
-1.1%		N/AN/A$27.54MN/AN/A110
ZIVO
ZIVO Bioscience
N/A$3.80
+7.6%		N/AN/A$15.21M$15.85KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SNCA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel